AGAMREE Profile

The study’s findings support the dissociative corticosteroid profile of AGAMREE, which selectively binds to the glucocorticoid receptor and triggers anti‑inflammatory activity while reducing systemic effects associated with long‑term conventional corticosteroid therapy. The company has an exclusive license agreement with Catalyst for commercialization rights in North America, under which Santhera is eligible to receive sales‑based milestone payments and royalties on net sales across all indications.